Abaluck, J., Gruber, J., & Swanson, A. (2018). Prescription drug use under Medicare Part D: A linear model of nonlinear budget sets. Journal of Public Economics, 164, 106–138. https://doi.org/10.1016/j.jpubeco.2018.05.005.
Alpert, A. E., Evans, W. N., Lieber, E. M. J., & Powell, D. (2019). Origins of the opioid crisis and its enduring impacts. National Bureau of Economic Research. No. w26500.
- Andraka‐Christou, B., Golan, O., Totaram, R., Ohama, M., Saloner, B., Gordon, A. J., & Stein, B. D. (2023). Prior authorization restrictions on medications for opioid use disorder: Trends in state laws from 2005 to 2019. Ann Med, 55(1), 514–520. https://doi.org/10.1080/07853890.2023.2171107.
Paper not yet in RePEc: Add citation now
- Axeen, S. (2018). Trends in opioid use and prescribing in Medicare, 2006–2012. Health Services Research, 53, 5–3328. https://doi.org/10.1111/1475‐6773.12846.
Paper not yet in RePEc: Add citation now
Balestra, S., Liebert, H., Maestas, N., & Sherry, T. B. (2022).Behavioral responses to supply‐side drug policy during the opioid epidemic. CESifo Working Paper Series 9704.
Buchmueller, T. C., & Carey, C. (2018). The effect of prescription drug monitoring programs on opioid utilization in Medicare. American Economic Journal: Economic Policy, 10(1), 77–112. https://doi.org/10.1257/pol.20160094.
- Centers for Disease Control and Prevention (Cdc) (2011). Vital signs: Overdoses of prescription opioid pain relievers‐‐‐United States, 1999‐‐2008. MMWR. Morbidity and Mortality Weekly Report, 60(43), 1487–1492.
Paper not yet in RePEc: Add citation now
- Council of Economic Advisors (Cea), 2019. The role of opioid prices in the evolving opioid crisis. https://trumpwhitehouse.archives.gov/wp‐content/uploads/2019/04/The‐Role‐of‐Opioid‐Prices‐in‐the‐Evolving‐Opioid‐Crisis.pdf.
Paper not yet in RePEc: Add citation now
- Economic report of the president, 2020. Chapter 7: Understanding the Opioid Crisis. Retrieved from https://www.govinfo.gov/app/collection/erp/2020.
Paper not yet in RePEc: Add citation now
Einav, L., Finkelstein, A., & Polyakova, M. (2018). Private provision of social insurance: Drug‐specific price elasticities and cost sharing in Medicare Part D. American Economic Journal: Economic Policy, 10(3), 122–153. https://doi.org/10.1257/pol.20160355.
- Food and Drug Administration (FDA) Analysis of long‐term trends in prescription opioid analgesic products: Quantity, Sales, and price trends, 2018. https://www.fda.gov/files/about%20fda/published/FDA‐Analysis‐of‐Long‐Term‐Trends‐in‐Prescription‐Opioid‐Analgesic‐Products‐‐Quantity‐‐Sales‐‐and‐Price‐Trends.pdf.
Paper not yet in RePEc: Add citation now
- Gatewood, A. K., Van Wert, M. J., Andrada, A. P., & Surkan, P. J. (2016). Academic physicians' and medical students' perceived barriers toward bystander administered naloxone as an overdose prevention strategy. Addictive Behaviors, 61, 40–46. https://doi.org/10.1016/j.addbeh.2016.05.013.
Paper not yet in RePEc: Add citation now
- Kaiser Family Foundation (KFF) (2017). Fact sheet: The Medicare Part D prescription drug benefit. https://www.kff.org/medicare/fact‐sheet/an‐overview‐of‐the‐medicare‐part‐d‐prescription‐drug‐benefit/.
Paper not yet in RePEc: Add citation now
Maclean, J. C., Mallatt, J., Ruhm, C. J., & Simon, K. (2020). Economic studies on the opioid crisis: A review.
- Meinhofer, A. (2016). The war on drugs: Estimating the effect of prescription. Drug Supply‐Side Interventions. https://doi.org/10.2139/ssrn.2716974.
Paper not yet in RePEc: Add citation now
Pacula, R. L., & Powell, D. (2018). A supply‐side perspective on the opioid crisis. Journal of Policy Analysis and Management, 37(2), 438–446. https://doi.org/10.1002/pam.22049.
- Ponnapalli, A., Grando, A., Murcko, A., & Wertheim, P. (2018). Systematic literature review of prescription drug monitoring programs. AMIA Annual Symposium Proceedings. Vol. 2018, p. 1478.
Paper not yet in RePEc: Add citation now
- Samuels, E. A., Ross, J. S., & Dhruva, S. S. (2017). Medicare formulary coverage restrictions for prescription opioids, 2006 to 2015. Annals of Internal Medicine, 167(12), 895. https://doi.org/10.7326/M17‐1823.
Paper not yet in RePEc: Add citation now
- Soni, A. (2018). Health insurance, price changes, and the demand for pain relief drugs: Evidence from Medicare Part D. Kelley School of Business Research Paper.
Paper not yet in RePEc: Add citation now
- Van Nuys, K., Joyce, G., Ribero, R., & Goldman, D. P. (2018). Frequency and magnitude of co‐payments exceeding prescription drug costs. Jama, 319(10), 1045–1047. https://doi.org/10.1001/jama.2018.0102.
Paper not yet in RePEc: Add citation now
- Volkow, N. D., McLellan, T. A., Cotto, J. H., Karithanom, M., & Weiss, S. R. (2011). Characteristics of opioid prescriptions in 2009. Jama, 305(13), 1299–1301. https://doi.org/10.1001/jama.2011.401.
Paper not yet in RePEc: Add citation now
- Zhang, H., Tallavajhala, S., Kapadia, S. N., Jeng, P. J., Shi, Y., Wen, H., & Bao, Y. (2020). State opioid limits and volume of opioid prescriptions received by Medicaid patients. Med Care, 58(12), 1111–1115. PMID: 32925468; PMCID: PMC7808343. https://doi.org/10.1097/MLR.0000000000001411.
Paper not yet in RePEc: Add citation now
- Zhou, C., Florence, C. S., & Dowell, D. (2016). Payments for opioids shifted substantially to public and private insurers while consumer spending declined, 1999–2012. Health Affairs, 35(5), 824–831. https://doi.org/10.1377/hlthaff.2015.1103.
Paper not yet in RePEc: Add citation now